Results 41 to 50 of about 1,443,667 (357)

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

mAbs, 2023
Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS,
Baoshan Zhang, Jason Gorman, Young D. Kwon, Amarendra Pegu, Cara W. Chao, Tracy Liu, Mangaiarkarasi Asokan, Michael F. Bender, Tatsiana Bylund, Leland Damron, Deepika Gollapudi, Paula Lei, Yile Li, Cuiping Liu, Mark K. Louder, Krisha McKee, Adam S. Olia, Reda Rawi, Arne Schön, Shuishu Wang, Eun Sung Yang, Yongping Yang, Kevin Carlton, Nicole A. Doria-Rose, Lawrence Shapiro, Michael S. Seaman, John R. Mascola, Peter D. Kwong   +27 more
doaj   +1 more source

Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics

mAbs, 2021
Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific antibody with two different heavy chains is greatly simplified if the light chains can be the ...
Kathryn H. Ching, Kimberley Berg, Kevin Reynolds, Darlene Pedersen, Alba Macias, Yasmina N. Abdiche, William D. Harriman, Philip A. Leighton   +7 more
doaj   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2016
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Zhong Wang, Qing Li, Siqi Chen, Jing Li
openaire   +2 more sources

A novel Pyroptosis‐related long non‐coding RNA signature for predicting the prognosis and immune landscape of head and neck squamous cell carcinoma

Cancer Medicine, Volume 11, Issue 24, Page 5097-5112, December 2022., 2022
our findings robustly demonstrate that our constructed prlncRNA signature could serve as an efficient indicator of prognosis, immunotherapy response, and chemosensitivity for HNSCC patients. Abstract Background Pyroptosis plays an essential function in carcinogenesis and the antitumor immune response.
Chongchang Zhou, Yiming Shen, Yangli Jin, Zhisen Shen, Dong Ye, Yi Shen, Hongxia Deng   +6 more
wiley   +1 more source

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

Life, 2021
Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen, Amer M. Zeidan, Jan Philipp Bewersdorf   +2 more
doaj   +1 more source

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood, 2021
Østergaard and colleagues report the development of a potent bispecific antibody, Mim8, which binds both activated factor IX and factor X, mimicking the propagation of coagulation by activated factor VIII.
Henrik Østergaard, J. Lund, Per Greisen, S. Kjellev, A. Henriksen, Nikolai Lorenzen, E. Johansson, G. Røder, M. G. Rasch, L. Johnsen, T. Egebjerg, S. Lund, H. Rahbek-Nielsen, Prafull S Gandhi, K. Lamberth, M. Loftager, L. Andersen, A. C. Bonde, F. Stavenuiter, D. E. Madsen, Xun Li, T. L. Holm, C. D. Ley, P. Thygesen, Haisun Zhu, Rong Zhou, Karina Thorn, Zhiru Yang, M. B. Hermit, J. Bjelke, B. G. Hansen, I. Hilden   +31 more
semanticscholar   +1 more source

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

Frontiers in Immunology, 2023
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Laurent Gros, Nelly Pirot, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge, Thierry Chardès, Thierry Chardès, Thierry Chardès   +24 more
doaj   +1 more source

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV

Antibodies, 2019
In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Lili Wang, Jiyan Xu, Yu Kong, Ruiying Liang, Wei Li, Jinyao Li, Jun Lu, Dimiter S. Dimitrov, Fei Yu, Yanling Wu, Tianlei Ying   +10 more
doaj   +1 more source

How to improve the quality of comparisons using external control cohorts in single-arm clinical trials? [PDF]

arXiv, 2022
PURPOSE Providing rapid answers and early acces to patients to innovative treatments without randomized clinical trial (RCT) is growing, with benefit estimated from single-arm trials. This has become common in oncology, impacting the approval pathway of health technology assessment agencies.
arxiv  

Antibody Watch: Text Mining Antibody Specificity from the Literature [PDF]

PLOS Computational Biology, 2021, 2020
Antibodies are widely used reagents to test for expression of proteins and other antigens. However, they might not always reliably produce results when they do not specifically bind to the target proteins that their providers designed them for, leading to unreliable research results.
arxiv   +1 more source